Cerebral regulation of insulin secretion and the development of insulin resistance in type 2 diabetes

Advances in Clinical and Experimental Medicine

Volumn 21, Issue 6, 2012, Pages 695-703

  Wasilewska, Marta ^a   Adamiec, Rajmund ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Brain; Diabetes; Insulin resistance; Neuropeptides; Obesity

Indexed keywords

AGOUTI RELATED PROTEIN; ANTIDIABETIC AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; GLUCAGON LIKE PEPTIDE 1; INSULIN; INSULIN RECEPTOR; NESFATIN 1; NEUROPEPTIDE; NEUROPEPTIDE Y; NEUROTRANSMITTER; UNCLASSIFIED DRUG;

CARBOHYDRATE METABOLISM; CENTRAL NERVOUS SYSTEM; DRUG EFFECT; EDITORIAL; INSULIN RELEASE; INSULIN RESISTANCE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; RISK FACTOR;

EID: 84874039047     PISSN: 18995276     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (32)

1. Gerozissis K: Brain Insulin: Regulation, Mechanisms of Action and Functions. Cell Mol Neurobioly 2003, 23, 1-25.
2. Brüning JC, Gautam D, Burks DJ, Gillette J, Schubert M, Orban PC, Klein R, Krone W, Müller-Wieland D, Kahn CR: Role of Brain Insulin Receptor in Control of Body Weight and Reproduction. Science 2000, 22, 2122-2125.
3. Schulingkamp RJ, Pagano TC, Hung D, Raffa RB: Insulin receptors and insulin action in the brain: review and clinical implications. Neurosci Biobehav Rev 2000, 24, 855-872.
4. Pagotto U: Where Does Insulin Resistance Start? Diabetes Care 2009, 32, 174-177.
5. Kocełak P, Zahorska-Markiewicz B, Olszanecka-Glinianowicz M: Hormonalna regulacja przyjmowania pokarmu. Endokrynol Pol 2009, 60, 296-301.
6. Hoek AM, Heijningen C, Schröder-van der Elst JP, Ouwens DM, Havekes LM, Romijn JA, Kalsbeek A, Pijl H: Intracerebroventricular Administration of Neuropeptide Y Induces Hepatic Insulin Resistance via Sympathetic Innervation. Diabetes 2008, 57, 2304-2310.
7. Katsuki A, Sumida Y, Gabazza EC, Murashima S, Tanaka T, Furuta M, Araki-Sasaki R, Hori Y, Nakatani K, Yano Y, Adachi Y: Plasma Levels of Agouti-Related Protein Are Increased in Obese Men. J Clin Endocrinol Metab 2001, 86, 1921-1924.
8. Li-Ying Fu, Pol AN: Agouti-Related Peptide and MC3/4 Receptor Agonists Both Inhibit Excitatory Hypothalamic Ventromedial Nucleus Neurons. J Neurosci 2008, 28, 5433-5449.
9. Mountjoy KG: Functions for pro-opiomelanocortin-derived peptides in obesity and diabetes. Biochem J 2010, 428, 305-324.
10. Costa JL, Hochgeschwender U, Brennan M: The role of melanocyte- stimulating hormone in insulin resistance and type 2 diabetes mellitus. Treat Endocrinol. 2006, 5, 7-13.
11. Jung EJ, Han DJ, Chang SH, Lim DG, Wee YM, Kim JH, Kim YH, Koo SK, Choi M, Kim SC: Protective effect of alpha-melanocyte-stimulating hormone on pancreas islet cell against peripheral blood mononuclear cell-mediated cytotoxicity in vitro. Transplant Proc 2007, 39, 1604-1606.
12. Millington G WM: The role of proopiomelanocortin (POMC) neurones in feeding behaviour. Nutr Metab 2007, 4, 18.
13. Hochgeschwender U, Costa JL, Reed P, Bui S, Brennan MB: Altered Glucose Homeostasis in Proopiomelanocortin-Null Mouse Mutants Lacking Central and Peripheral Melanocortin. Endocrinology 2003, 144(12), 5194-5202.
14. Zhang AQ, Li XL, Jiang CY, Lin L, Shi RH, Chen JD, Oomura Y: Expression of nesfatin-1/NUCB2 in rodent digestive system. World J Gastroenterol 2010, 16, 1735-1741.
15. Stengel A, Goebel M, Yakubov I, Wang L, Witcher D, Coskun T, Taché Y, Sachs G, Nils SG, Lambrecht WG: Identification and Characterization of Nesfatin-1 Immunoreactivity in Endocrine Cell Types of the Rat Gastric Oxyntic Mucosa. Endocrinology 2009, 150, 232-238.
16. Maejima Y, Sedbazar U, Suyama S, Kohno D, Onaka T, Takano E, Yoshida N, Koike M, Uchiyama Y, Fujiwara K, Yashiro T, Horvath TL, Dietrich MO, Tanaka S, Dezaki K, Oh-IS, Hashimoto K, Shimizu H, Nakata M, Mori M, Yada T: Nesfatin-1-Regulated Oxytocinergic Signaling in the Paraventricular Nucleus Causes Anorexia through a Leptin-Independent Melanocortin Pathway. Cell Metab 2009, 10, 355-365.
17. Voss U, Riva M, Dekker Nitert M, Ling C, Lindqvist A, Wierup N: Nesfatin-1 stimulates insulin secretion, inhibits glucagon secretion and is expressed in human and rodent beta cells. Diabetologia 2010, 53, 548.
18. Knauf C, Cani PD, Perrin C, Iglesias MA, Maury JF, Bernard E, Benhamed F, Grémeaux T, Drucker DJ, Kahn CR, Girard J, Tanti JF, Delzenne NM, Postic C, Burcelin R: Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J Clin Invest 2005, 115, 3554-3563.
19. Sandoval D: CNS GLP-1 Regulation of Peripheral Glucose Homeostasis. Physiol Behav. 2008, 94, 670-674.
20. Ramanjaneya M, Chen J, Brown JE, Tripathi G, Hallschmid M, Patel S, Kern W, Hillhouse EW, Lehnert H, Tan BK, Randeva HS: Identification of Nesfatin-1 in Human and Murine Adipose Tissue: A Novel Depot-Specific Adipokine with Increased Levels in Obesity. Endocrinology 2010, 150, 3169-180.
21. Li QC, Wang HY, Chen X, Guan HZ, Jiang ZY: Fasting plasma levels of nesfatin-1 in patients with type 1 and type 2 diabetes mellitus and the nutrient-related fluctuation of nesfatin-1 level in normal humans. Regul Peptides 2010, 159, 72-77.
22. García-Galiano D, Navarro VM, Gaytan F, Tena-Sempere M: Expanding roles of NUCB2/nesfatin-1 in neuroendocrine regulation. J Mol Endocrinol 2010, 45, 281-290.
23. Żełobowska K, Gumprecht J, Grzeszczak W: Neurotropowy czynnik pochodzenia mózgowego (BDNF) - udział w patogenezie insulinooporności i cukrzycy typu 2. Przew Lek 2007, 4, 79-83.
24. Pedersen BK, Pedersen M, Krabbe KS, Bruunsgaard H, Matthews VB, Febbraio MA: Role of exercise-induced brain-derived neurotrophic factor production in the regulation of energy homeostasis in mammals. Exp Physiol 2009, 94,1153-1160.
25. Krabbe KS, Nielsen AR, Krogh-Madsen R, Plomgaard P, Rasmussen R, Erikstrup C, Fischer CP, Lindegaard B, Petersen AMW, Taudorf S, Secher NH, Pilegaard H, Bruunsgaard H, Pedersen BK: Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia 2007, 50, 431-438.
26. Suwaa M, Kishimotob H, Nofujib Y, Nakanoc H, Sasakid H, Radake Z, Kumagaia S: Serum brain-derived neurotrophic factor level is increased and associated with obesity in newly diagnosed female patients with type 2 diabetes mellitus. Metab Clin Exp 2006, 52, 852-857.
27. Żoła̧dź JA, Pilc A: The effect of physical activity on the brain derived neurotrophic factor: from animal to human studies. J Physiol Pharmacol 2010, 61, 533-541.
28. Noble EE, Billington CJ, Kotz CM, Wang C: The lighter side of BDNF. Am J Physiol Regul Integr Comp Physiol 2011, 300, 1053-1069.
29. Wang M, Chan Y, Lee H, Hong L: Regulation of the Intracerebroventricular Administration of Brain-Derived Neurotrophic Factor on Baroreflex Function and Insulin Sensitivity in Rats. Chin J Physiol 2012, 55, 184-191.
30. Pedersen B: Muscles and their myokines. J Exp Biol 2011, 214, 337-346.
31. Ola MS, Nawaz MI: Cellular and Molecular Mechanism of Diabetic Retinopathy. In: Diabetic Retinopathy. Eds.: Ola MS, InTech 2012, 1-30.
32. Navaratna D, Guo S, Hayakawa K, Wang X, Gerhardinger C, Lo EH: Decreased Cerebrovascular Brain-Derived Neurotrophic Factor-Mediated Neuroprotection in the Diabetic Brain. Diabetes 2011, 60, 1789-1796.